Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zaficefta

- PMLiVE

Pfizer/Flagship’s drug discovery partnership to focus on obesity treatments

The agreement with Profound Therapeutics is the first to be initiated under the partnership

Can Cinderella save us?

KCL research could speed up discovery of new antibiotics in fight against AMR

According to WHO, AMR is designated as one of the top ten global public health threats facing humanity

- PMLiVE

MIT protein study could help accelerate development of new antibiotics

Histidine kinase is a crucial bacterial protein that regulates processes, including antibiotic resistance

- PMLiVE

Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

- PMLiVE

Pfizer shares positive five-year results for Lorbrena in advanced lung cancer

The majority of Lorbrena-treated patients were alive without disease progression after five years

- PMLiVE

WHO updates drug-resistant bacteria list to develop new treatments for AMR

The 2024 BPPL list includes 15 families of antibiotic-resistant bacteria

- PMLiVE

GSK becomes first founding partner of global initiative tackling antimicrobial resistance

AMR could cause an estimated ten million deaths every year by 2050 unless action is taken

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Pfizer’s Vyndaqel recommended by NICE to treat rare heart disease ATTR-CM

Approximately 1,500 people in England are affected by transthyretin amyloidosis cardiomyopathy

- PMLiVE

UK government launches five-year national action plan for antimicrobial resistance

It is estimated that 1.27 million global deaths in 2019 were caused by antibiotic-resistant infections

- PMLiVE

Pfizer’s sickle cell disease therapy Oxbryta recommended by NICE for NHS use

About 4,000 people in England with the genetic blood disorder are expected to benefit from the decision

- PMLiVE

Pfizer/Genmab’s Tivdak granted full FDA approval for recurrent or metastatic cervical cancer

It is estimated that more than 13,960 new cases of invasive cervical cancer were diagnosed in the US last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links